Ventyx Biosciences, Inc. Cash Flow Statement

Cash Flow Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Net Income -7.41M-59.15M-56.35M
Depreciation and Depletion 0.03M0.12M0.20M0.30M
Share-based Compensation 0.04M2.73M16.57M28.59M22.93M
Gains from Investment Securities 0.00M0.00M-2.23M-9.18M-9.52M
Asset Writedowns and Impairment 0.28M
Cash from Operations -6.20M-38.65M-98.77M-166.52M-130.87M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 0.35M0.78M1.08M
Depreciation & Amortization (CF) 0.03M0.12M0.20M0.30M
Change in Working Capital
Change in Account Payables 0.59M2.44M1.61M-0.74M-2.64M
Change in Accured Expenses 0.18M5.96M1.89M5.99M-6.91M
Other Working Capital Changes -0.04M4.39M8.34M-0.62M-0.85M
Investing Activities
Capital Expenditures 0.26M0.28M0.51M0.24M
Acquisitions -1.90M
Change in Acquisitions & Divestments 16.50M272.58M373.73M268.38M
Cash from Investing Activities -214.37M-74.93M100.94M-15.51M
Financing Activities
Cash from Financing Activities 6.13M323.55M167.77M53.33M122.11M
Additional items
Exchange Rate Effect 0.01M-0.04M-0.01M-0.06M
Change in Cash -0.07M70.55M-5.97M-12.27M-24.32M
Beginning Cash Balance 0.07M-70.55M5.97M12.27M24.32M
Free Cash Flow -6.20M-38.91M-99.05M-167.04M-131.11M
Net Cash Flow -0.07M70.54M-5.93M-12.25M-24.26M